Stammdaten
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Unternehmen & Branche
| Name | Quoin Pharmaceuticals, Ltd. |
|---|---|
| Ticker | QNRX |
| CIK | 0001671502 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | ADR |
| Marktkapitalisierung | 3,2 Mio. USD |
| Beta | 1,82 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -15,804,655 | 20,390,569 | 13,119,906 | ||
| 2025-09-30 | 10-Q | -3,948,165 | 6,423,664 | -1,214,620 | ||
| 2025-06-30 | 10-Q | -3,695,938 | 8,912,589 | 2,551,357 | ||
| 2025-03-31 | 10-Q | -3,812,179 | 12,955,153 | 5,925,809 | ||
| 2024-12-31 | 10-K | -8,962,472 | 15,709,338 | 9,204,673 | ||
| 2024-09-30 | 10-Q | -2,349,885 | 11,389,153 | 5,441,681 | ||
| 2024-06-30 | 10-Q | -1,974,033 | 14,054,619 | 7,478,336 | ||
| 2024-03-31 | 10-Q | -2,327,280 | 16,123,210 | 9,125,522 | ||
| 2023-12-31 | 10-K | -8,686,573 | 12,169,229 | 5,664,016 | ||
| 2023-09-30 | 10-Q | -1,926,679 | 15,067,857 | 7,413,696 | ||
| 2023-06-30 | 10-Q | -2,106,947 | 16,709,444 | 9,071,872 | ||
| 2023-03-31 | 10-Q | -2,603,069 | 18,450,726 | 10,914,443 | ||
| 2022-12-31 | 10-K | -9,381,496 | 14,458,063 | 7,406,774 | ||
| 2022-09-30 | 10-Q | -3,029,567 | 9,167,688 | |||
| 2022-06-30 | 10-Q | -2,668,167 | -3,168,134 | |||
| 2022-03-31 | 10-Q | -1,682,802 | -729,408 | |||
| 2021-12-31 | 10-K | -21,462,588 | 9,356,851 | 657,032 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.